川田 一郎 (カワダ イチロウ)

ICHIRO Kawada

写真a

所属(所属キャンパス)

医学部 内科学教室(呼吸器) 慶應義塾大学医学部 呼吸器内科 (信濃町)

職名

専任講師(有期)

外部リンク

経歴 【 表示 / 非表示

  • 1998年05月
    -
    2000年04月

    慶應義塾大学医学部, 内科学教室, 研修医

  • 2000年05月
    -
    2001年05月

    埼玉県立循環器・呼吸器病センター, 内科, 専修医

  • 2001年06月
    -
    2002年05月

    東京歯科大学市川総合病院, 内科, 助手

  • 2002年06月
    -
    2005年06月

    慶應義塾大学医学部, 呼吸循環器内科, 助手

  • 2005年07月
    -
    2009年12月

    日野市立病院, 内科, 主任医員

全件表示 >>

学歴 【 表示 / 非表示

  • 1992年04月
    -
    1998年03月

    慶應義塾大学, 医学部

    大学, 卒業

学位 【 表示 / 非表示

  • 学士(医学), 慶應義塾, 課程, 1998年03月

  • 博士(医学), 慶應義塾, 論文, 2009年02月

    非小細胞肺がん患者における上皮成長因子受容体遺伝子変異のRFLP法によるスクリーニング法の確立

免許・資格 【 表示 / 非表示

  • 医師免許, 1998年05月

  • 日本内科学会 認定内科医, 2002年09月

  • 日本内科学会 総合内科専門医, 2006年12月

  • 日本内科学会 指導医, 2006年09月

  • 日本内科学会 JMECCインストラクター, 2015年12月

全件表示 >>

 

研究分野 【 表示 / 非表示

  • 呼吸器内科学

 

著書 【 表示 / 非表示

  • インフルエンザ診療マニュアル

    金澤實, 川田一郎, 柳澤勉, 南江堂, 2001年01月

    担当範囲: インフルエンザと社会

論文 【 表示 / 非表示

  • Disseminated histoplasmosis from a calcified lung nodule after long-term corticosteroid therapy in an elderly Japanese patient: A case report

    Kobayashi K., Asakura T., Kawada I., Hasegawa H., Chubachi S., Ohara K., Kuramoto J., Sugiura H., Fujishima S., Iwata S., Umeyama T., Katano H., Uwamino Y., Miyazaki Y., Kamei K., Hasegawa N., Betsuyaku T.

    Medicine (Medicine)  98 ( 17 )  2019年04月

     概要を見る

    RATIONALE: Histoplasmosis occurs most commonly in Northern and Central America and Southeast Asia. Increased international travel in Japan has led to a few annual reports of imported histoplasmosis. Healed sites of histoplasmosis lung infection may remain as nodules and are often accompanied by calcification. Previous studies in endemic areas supported the hypothesis that new infection/reinfection, rather than reactivation, is the main etiology of symptomatic histoplasmosis. No previous reports have presented clinical evidence of reactivation. PATIENT CONCERNS: An 83-year-old Japanese man was hospitalized with general fatigue and high fever. He had been treated with prednisolone at 13 mg/d for 7 years because of an eczematous skin disease. He had a history of travel to Los Angeles, Egypt, and Malaysia 10 to 15 years prior to admission. Five years earlier, computed tomography (CT) identified a solitary calcified nodule in the left lingual lung segment. The nodule size remained unchanged throughout a 5-year observation period. Upon admission, his respiratory condition remained stable while breathing room air. CT revealed small, randomly distributed nodular shadows in the bilateral lungs, in addition to the solitary nodule. DIAGNOSIS: Disseminated histoplasmosis, based on fungal staining and cultures of autopsy specimens. INTERVENTIONS: The patient's fever continued despite several days of treatment with meropenem, minocycline, and micafungin. Although he refused bone marrow aspiration, isoniazid, rifampicin, ethambutol, and prednisolone were administered for a tentative diagnosis of miliary tuberculosis. OUTCOMES: His fever persisted, and a laboratory examination indicated severe thrombocytopenia with disseminated intravascular coagulation. He died on day 43 postadmission. During autopsy, the fungal burden was noted to be higher in the calcified nodule than in the disseminated nodules of the lung, suggesting a pathogenesis involving endogenous reactivation of the nodule and subsequent hematogenous and lymphatic spread. LESSONS: Physicians should consider histoplasmosis in patients with calcified nodules because the infection may reactivate during long-term corticosteroid therapy.

  • Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations

    Hasegawa H., Yasuda H., Hamamoto J., Masuzawa K., Tani T., Nukaga S., Hirano T., Kobayashi K., Manabe T., Terai H., Ikemura S., Kawada I., Naoki K., Soejima K.

    Lung Cancer (Lung Cancer)  127   146 - 152 2019年01月

    査読有り,  ISSN  01695002

     概要を見る

    © 2018 Elsevier B.V. Objectives: Epidermal growth factor receptor (EGFR) mutation-positive lung cancer accounts for a significant subgroup of non-small cell lung cancers (NSCLC). Approximately 4–10% of EGFR mutations in NSCLC are EGFR exon 20 insertion mutations, which are reportedly associated with resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment. NSCLC patients carrying these mutations are rarely treated with EGFR-TKIs. The purpose of this study was to evaluate the efficacy of afatinib or osimertinib plus cetuximab combination therapy in experimental NSCLC models with EGFR exon 20 insertion mutations. Materials and methods: The EGFR mutations examined in this study were A763_Y764insFQEA, Y764_V765insHH, A767_V769dupASV, and D770_N771insNPG. Ba/F3 cells constitutively expressing wild type or mutated EGFR were used to determine the efficacy of afatinib or osimertinib plus cetuximab combination therapy in vitro. To determine the efficacy of the combination therapy in vivo, female BALB/c-nu mice were injected subcutaneously with 1 million Ba/F3 cells carrying EGFR A767_V769dupASV or Y764_V765insHH. Results: We observed a mild but significant (P < 0.05) additive effect of the combination therapy against several EGFR exon 20 insertion mutations in vitro. Regarding EGFR A767_V769dupASV and EGFR Y764_V765insHH, cetuximab and afatinib single treatment did not induce significant inhibition of tumor formation; however, afatinib plus cetuximab combination treatment induced significant (P < 0.05) tumor growth inhibition without significant body weight loss or skin rash. Conclusion: The combination therapy induced a more potent inhibitory effect against several EGFR exon 20 insertion mutations than either therapy alone. Cetuximab can potentially increase the efficacy of afatinib or osimertinib in NSCLC with EGFR exon 20 insertion mutations.

  • Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.

    Sato T, Soejima K, Fujisawa D, Takeuchi M, Arai D, Nakachi I, Naoki K, Kawada I, Yasuda H, Ishioka K, Nukaga S, Kobayashi K, Masaki K, Inoue T, Hikima K, Nakamura M, Ohgino K, Oyamada Y, Funatsu Y, Terashima T, Miyao N, Sayama K, Saito F, Sakamaki F, Betsuyaku T.

    Oncologist 23 ( 10 ) 1218 - 1229 2018年10月

    共著, 査読有り

  • Secondary brain neoplasm after stereotactic radiosurgery in patients with metastatic non-small cell lung cancer

    Nukaga S., Naoki K., Yasuda H., Kawada I., Ohara K., Soejima K., Betsuyaku T.

    Internal Medicine (Internal Medicine)  57 ( 16 ) 2383 - 2387 2018年08月

    共著, 査読有り,  ISSN  09182918

     概要を見る

    © 2018 The Japanese Society of Internal Medicine. Stereotactic radiosurgery (SRS) using the Gamma Knife (GK) is now being increasingly utilized for the treatment of brain metastases. However, there are a few reported cases of SRS-induced brain neoplasms. We herein report the case of a Japanese woman with metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor (EGFR)-mutations who was treated four times with a GK for brain metastases. She developed glioblastoma 5.7 years after the initial GK surgery. Radiation-induced secondary neoplasms generally appear after a latency period of several years. Advances in cancer therapy have improved the survival of patients with NSCLC, providing enough time for secondary neoplasms to appear after SRS.

  • Comparison of detection methods of EGFR T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer

    Kobayashi K., Naoki K., Manabe T., Masuzawa K., Hasegawa H., Yasuda H., Kawada I., Soejima K., Betsuyaku T.

    OncoTargets and Therapy (OncoTargets and Therapy)  11   3335 - 3343 2018年06月

    共著, 査読有り

     概要を見る

    © 2018 Kobayashi et al. Background: Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, exerts remarkable effects against EGFR T790M resistance mutation-positive non-small cell lung cancer. Identifying T790M mutation by re-biopsy is essential before prescribing osimertinib. Tissue biopsy is the golden standard for this purpose, but several factors limit its success rate. The liquid biopsy with blood, using circulating tumor DNA, has been an alternative method. However, the true biological meaning and equivalence of liquid biopsy and tumor biopsy are still under investigation. Especially, the usefulness of serum samples to detect T790M mutation is not yet been known. Patients and methods: We prospectively evaluated the sensitivity, specificity, and parallelism of the detection of EGFR mutations in tissue re-biopsy and liquid biopsy (plasma and serum), simultaneously, from June 2016 to May 2017. EGFR mutations in tumor re-biopsy were evaluated by COBAS ver2 and PNA-LNA PCR clamp method, and those in liquid biopsy were evaluated with COBAS ver2. Results: Fifteen patients were enrolled. In 10 patients whose EGFR mutation was detected in liquid biopsy, the original EGFR mutation (exon 19 del or L858R) was detected in all patients. Detection of EGFR mutation by COBAS ver2 and by PNA-LNA method was almost the same in tissue re-biopsy. The detection rate of T790M was lower than that of the original EGFR mutation in liquid biopsy compared to that in tissue re-biopsy. The detection of T790M in serum exhibited a higher specificity (67%) and positive predictive value (50%) than that in plasma (50% and 40%, respectively). The detection sensitivity was similar in plasma and serum. Conclusion: Plasma, serum, and tissue genotyping can have complementary roles for detecting EGFR-T790M using COBAS ver2. Repeated tests with different samples and different methods may improve accuracy of T790M detection and will lead to the maximum benefit for the patient.

全件表示 >>

総説・解説等 【 表示 / 非表示

  • Bedside Teaching EGFR遺伝子変異解析

    川田一郎, 副島研造

    呼吸と循環 56 ( 6 ) 617 - 612 2008年06月

    総説・解説(学術雑誌), 共著

研究発表 【 表示 / 非表示

  • NHBE肺癌発生モデルにおける癌抑制遺伝子、癌遺伝子のメチル化、および脱メチル化の定量的検討

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 2003年11月, 口頭(一般)

  • DNAメチル転移酵素3b(DNMT3b)の癌化における重要性

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 2003年11月, 口頭(一般)

  • 癌化いおけるde novo DNAメチル転移酵素、DNMT3b1/3b2の機能的差異の検討−実験モデルの確立−

    山口 佳寿博

    第44回日本肺癌学会総会 (東京) , 2003年11月, 口頭(一般)

  • NHBE肺癌発生モデルにおける癌抑制遺伝子および癌遺伝子プロモーター領域のメチル化,脱メチル化の検討

    川田一郎,副島研造,渡邊秀生,山口佳寿博

    43回日本呼吸器学会総会, 2003年03月, 口頭(一般)

  • NHBE肺癌発生モデルを用いた不死化,癌化過程における局所的メチル化および全体的低メチル化の検討

    渡邊秀生,副島研造,川田一郎,山口佳寿博

    43回日本呼吸器学会総会, 2003年03月, 口頭(一般)

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • 悪性胸膜中皮腫におけるMET遺伝子異常の解明と新薬の個別化治療への臨床応用

    2019年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 川田 一郎, 基盤研究(C), 補助金,  代表

受賞 【 表示 / 非表示

  • 研究奨励賞(Respiratory Research Award)

    2014年11月, 第18回東京呼吸病態研究会, 非小細胞肺癌とMET遺伝子異常, RON遺伝子異常

    受賞区分: その他の賞

 

担当授業科目 【 表示 / 非表示

  • 内科学(呼吸器)講義

    2019年度

担当経験のある授業科目 【 表示 / 非表示

  • 内科学、血液ガス、酸塩基平衡

    慶應義塾, 2015年度, 秋学期, 専門科目, 講義